CVS Group plc

DB:4C9 Stock Report

Market Cap: €708.9m

CVS Group Valuation

Is 4C9 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4C9 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4C9 (€9.35) is trading below our estimate of fair value (€22.64)

Significantly Below Fair Value: 4C9 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4C9?

Key metric: As 4C9 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4C9. This is calculated by dividing 4C9's market cap by their current earnings.
What is 4C9's PE Ratio?
PE Ratio22.5x
EarningsUK£26.20m
Market CapUK£589.70m

Price to Earnings Ratio vs Peers

How does 4C9's PE Ratio compare to its peers?

The above table shows the PE ratio for 4C9 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average16.6x
RHK RHÖN-KLINIKUM
18.9x7.5%€850.1m
M12 M1 Kliniken
17.5x17.5%€293.2m
LIK LIMES Schlosskliniken
23.2xn/a€99.1m
JTH Gesundheitswelt Chiemgau
6.8xn/a€23.8m
4C9 CVS Group
22.5x15.5%€589.7m

Price-To-Earnings vs Peers: 4C9 is expensive based on its Price-To-Earnings Ratio (22.5x) compared to the peer average (16.6x).

Price to Earnings Ratio vs Industry

How does 4C9's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
4C9 22.5xIndustry Avg. 18.5xNo. of Companies9PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4C9 is expensive based on its Price-To-Earnings Ratio (22.5x) compared to the European Healthcare industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is 4C9's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4C9 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.5x
Fair PE Ratio21.7x

Price-To-Earnings vs Fair Ratio: 4C9 is expensive based on its Price-To-Earnings Ratio (22.5x) compared to the estimated Fair Price-To-Earnings Ratio (21.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4C9 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€9.35
€18.11
+93.7%
30.2%€28.49€11.30n/a8
Nov ’25€10.90
€19.03
+74.6%
25.7%€28.26€11.84n/a8
Oct ’25€13.30
€19.21
+44.4%
25.2%€28.45€12.34n/a8
Sep ’25€13.20
€18.59
+40.8%
23.8%€27.53€11.94n/a9
Aug ’25€13.30
€18.92
+42.3%
24.1%€28.08€11.85n/a9
Jul ’25€11.70
€18.84
+61.1%
25.6%€27.97€11.80n/a8
Jun ’25€12.90
€19.34
+49.9%
25.1%€27.76€11.71n/a9
May ’25€11.30
€21.67
+91.8%
28.5%€32.03€11.65n/a10
Apr ’25€11.70
€22.39
+91.4%
24.2%€32.17€14.04n/a10
Mar ’25€17.20
€26.25
+52.6%
18.4%€32.24€17.94n/a10
Feb ’25€19.50
€26.25
+34.6%
18.4%€32.24€17.94n/a10
Jan ’25€19.60
€25.84
+31.8%
18.9%€32.02€17.81n/a10
Dec ’24€17.10
€26.50
+55.0%
15.9%€31.66€19.63n/a9
Nov ’24€16.70
€25.89
+55.0%
15.6%€31.70€19.65€10.908
Oct ’24€18.20
€25.89
+42.2%
15.6%€31.70€19.65€13.308
Sep ’24€24.40
€28.40
+16.4%
9.9%€32.16€24.74€13.209
Aug ’24€24.00
€28.37
+18.2%
9.5%€32.05€24.65€13.309
Jul ’24€22.60
€26.63
+17.8%
11.0%€30.82€21.75€11.708
Jun ’24€24.20
€26.63
+10.0%
11.0%€30.82€21.75€12.908
May ’24€24.00
€26.63
+11.0%
11.0%€30.82€21.75€11.308
Apr ’24€20.80
€26.63
+28.0%
11.0%€30.82€21.75€11.708
Mar ’24€21.00
€26.92
+28.2%
10.8%€31.13€23.32€17.207
Feb ’24€22.40
€27.04
+20.7%
11.1%€31.35€23.48€19.507
Jan ’24€22.20
€26.01
+17.1%
10.8%€31.17€22.33€19.606
Dec ’23€23.40
€26.01
+11.1%
10.8%€31.17€22.33€17.106
Nov ’23€22.00
€26.67
+21.2%
10.8%€31.97€22.90€16.706

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-0.9%

1Y

-35.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%

OrbusNeich Medical Group Holdings

HK$3.1b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

Q8T

HK$0.40

7D

-21.2%

1Y

-46.9%